ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
Authors
Keywords
ABCG2, ABCG2 inhibitors, BCRP, multidrug resistance (MDR), tyrosine kinases
Journal
JOURNAL OF BIOSCIENCES
Volume 41, Issue 2, Pages 313-324
Publisher
Springer Nature
Online
2016-04-05
DOI
10.1007/s12038-016-9601-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy
- (2015) Marie Morfouace et al. CANCER RESEARCH
- Overcoming Multidrug Resistance in Cancer Stem Cells
- (2015) Karobi Moitra Biomed Research International
- Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance
- (2015) Eran E. Bram et al. NEOPLASIA
- Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
- (2014) Kamlesh Sodani et al. BIOCHEMICAL PHARMACOLOGY
- Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
- (2014) Clinton F. Stewart et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells
- (2013) V Martín et al. BRITISH JOURNAL OF CANCER
- Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype
- (2013) Wook-Jin Yang et al. MOLECULES AND CELLS
- Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
- (2012) S. J. Seong et al. ANNALS OF ONCOLOGY
- Phorbol Ester TPA Modulates Chemoresistance in the Drug Sensitive Breast Cancer Cell Line MCF-7 by Inducing Expression of Drug Efflux Transporter ABCG2
- (2012) Fatemeh Kalalinia et al. Asian Pacific Journal of Cancer Prevention
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
- (2012) Karthika Natarajan et al. BIOCHEMICAL PHARMACOLOGY
- Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer
- (2012) Yang Jiang et al. Gastric Cancer
- Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
- (2012) S. Angelini et al. HAEMATOLOGICA
- Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile
- (2012) Stéphanie Lheureux et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
- (2012) R. Sen et al. MOLECULAR CANCER THERAPEUTICS
- Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
- (2012) Selvi Durmus et al. MOLECULAR PHARMACEUTICS
- Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells
- (2011) Xin Li et al. BIOCHEMICAL PHARMACOLOGY
- Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
- (2011) Amit K. Tiwari et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Tumor Necrosis Factor Alpha Induces Stronger Cytotoxicity in ABCG2-Overexpressing Resistant Breast Cancer Cells Compared with Their Drug-Sensitive Parental Line
- (2011) Fatemeh Mosaffa et al. DNA AND CELL BIOLOGY
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells
- (2011) Fatemeh Mosaffa et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma
- (2011) R R Singh et al. ONCOGENE
- Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines
- (2010) Fatemeh Elahian et al. DRUG AND CHEMICAL TOXICOLOGY
- Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines
- (2010) Fatemeh Kalalinia et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
- (2010) Naoto Takahashi et al. JOURNAL OF HUMAN GENETICS
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)
- (2009) Yash A. Gandhi et al. AAPS Journal
- Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
- (2009) D. H. Kim et al. ANNALS OF ONCOLOGY
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
- (2009) Chun-ling Dai et al. CANCER LETTERS
- ABCG2: the key to chemoresistance in cancer stem cells?
- (2009) Yi An et al. Expert Opinion on Drug Metabolism & Toxicology
- Identification ofGAS1as an Epirubicin Resistance-related Gene in Human Gastric Cancer Cells with a Partially Randomized Small Interfering RNA Library
- (2009) Lina Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood-Brain Barrier for A 1-40 Peptides
- (2009) H. Xiong et al. JOURNAL OF NEUROSCIENCE
- MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells
- (2009) Y.-Z. Pan et al. MOLECULAR PHARMACOLOGY
- Dexamethasone Downregulates BCRP mRNA and Protein Expression in Breast Cancer Cell Lines
- (2009) Fatemeh Elahian et al. ONCOLOGY RESEARCH
- Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2
- (2008) Hiroshi Nakagawa et al. BIOCHEMICAL JOURNAL
- Membrane Topology of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) Determined by Epitope Insertion and Immunofluorescence†
- (2008) Honggang Wang et al. BIOCHEMISTRY
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
- (2008) J. R. Molina et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
- (2008) A. Petain et al. CLINICAL CANCER RESEARCH
- Polymorphisms of Human N-Acetyltransferases and Cancer Risk
- (2008) Jose Agundez CURRENT DRUG METABOLISM
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
- (2008) S. Shukla et al. DRUG METABOLISM AND DISPOSITION
- Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells
- (2008) Clara Lemos et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization of a side population of astrocytoma cells in response to temozolomide
- (2008) Constance Chua et al. JOURNAL OF NEUROSURGERY
- Effect of Cysteine Mutagenesis on the Function and Disulfide Bond Formation of Human ABCG2
- (2008) Y. Liu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pharmacogenomic importance of ABCG2
- (2008) George Cusatis et al. PHARMACOGENOMICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started